Physician profile
David Schechter
NPI 1790706117
$4,332.73
in general payments reported to CMS, 2019-2025
28 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $144 · 2021: $689 · 2022: $789 · 2023: $645 · 2024: $726 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,516 · Gift: $59.40 · Consulting Fee: $27.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.45 |
| Gift | $59.40 |
| Consulting Fee | $27.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $585.33 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $581.44 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $334.54 | 2019-2024 | |
| Lundbeck LLC | $316.80 | 2019-2020 | |
| Esperion Therapeutics, INC. | $260.74 | 2021-2024 | Nexletol |
| Abbott Laboratories | $259.15 | 2021-2023 | Mitraclip |
| Edwards Lifesciences Corporation | $220.32 | 2020-2024 | Sapien 3 Ultra Resilia |
| Lilly USA, LLC | $203.01 | 2023-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $182.93 | 2019 | |
| Novo Nordisk INC | $170.51 | 2021-2024 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $158.14 | 2021-2025 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $132.58 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $123.78 | 2019 | |
| Amgen INC. | $121.58 | 2020-2024 | Repatha, Prolia, Evenity |
| Abbvie INC. | $115.36 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $95.40 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.60 | 2020-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $74.98 | 2024-2025 | Farxiga |
| Astellas Pharma US INC | $73.34 | 2023-2025 | Veozah |
| Mannkind Corporation | $59.40 | 2023 | Afrezza |
| Intra-Sana Laboratories | $42.38 | 2023-2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Baxter Healthcare | $27.60 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Boston Scientific Corporation | $24.80 | 2019 | |
| Mylan Specialty L.P. | $22.40 | 2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $18.22 | 2025 | Opsumit |
| Glaxosmithkline, LLC. | $17.41 | 2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $15.76 | 2021 | |
| Infobionic, INC | $15.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.